Pfizer Corporation

Pharmacia & Upjohn Company

British Biotech Pharmaceuticals Limited

David Graham Brown

Andrew Simon Bell

Michael John Palmer

David Nathan Abraham Fox

Ian Roger Marsh

Andrew Ian Morrell

Carol Ann Winslow

Kevin Neil Dack

Dafydd Rhys Owen

John Nicholas Freskos

Thomas Edward Rogers

David Louis Brown

Yvette M Fobian

Michael B Tollefson

Paul Anthony Stupple

Karl Richard Gibson

Robert Owen Hughes

Brent V Mischke

Mark David Andrews

E Jon Jacobsen

Richard Mark Edwards

John Martin Clements

Todd M Maddux

Thomas Ryckmans

Nicholas Kenneth Terrett

Sharanjeet Kaur Bagal

Sarah Elizabeth Skerratt

John M Molyneaux

Yogesh Sabnis

John K Walker

Kiyoyuki Omoto

David Nathan Fox

Stewart Craig

Christopher Phillips

Wolfgang Klute

Joseph B Moon

Anne L Cook

Inaki Morao

Steven E Heasley

D Joseph Rogier, Jr

Hwang Fun Lu

The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.

Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors

This invention relates to compounds of formula (I) 

Pyrazolo[4,3-d]pyrimidines as phosphodiesterase inhibitors

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R, R, Rand Rare as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, synthetic methods, and intermediates are also disclosed.

Pyridine [3,4-b] pyrazinones

Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors

This invention relates to compounds of formula (I). 

Pyrazolo[4,3-D]pyrimidines

The present invention comprises a class of 5,7-diaminopyrazolo[4,3-d]pyrimidine compounds. These compounds are useful as phosphodiesterase type 5 inhibitors. The present invention further comprises compositions containing the compounds use of the compounds and compositions to treat hypertension and other conditions, processes for the preparation of the compounds, and intermediates used in the preparation of the compounds.

Substituted pyrazolo[4,3-d]pyrimidines and their use as PDE-5 inhibitors

PDGF-B analogues

Compounds of the formula: ##STR1## wherein R.sup.1 is H, C.sub.1 -C.sub.3 alkyl, C.sub.3 -C.sub.5 cycloalkyl or C.sub.1 -C.sub.3 perfluoroalkyl; R.sup.2 is H, C.sub.1 -C.sub.6 alkyl optionally substituted by OH, C.sub.1 -C.sub.3 alkoxy or C.sub.3 -C.sub.6 cycloalkyl, or C.sub.1 -C.sub.3 perfluoroalkyl; R.sup.3 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 alkynyl, C.sub.3 -C.sub.6 alkynyl, C.sub.3 -C.sub.7 cycloalkyl, C.sub.1 -C.sub.6 perfluoroalkyl or (C.sub.3 -C.sub.6 cycloalky)C.sub.1 -C.sub.6 alkyl; R.sup.4 taken together with the nitrogen atom to which it is attached completes a pyrrolidinyl, piperidino, morpholino, or 4-N-(R.sup.6)-piperazinyl group; R.sup.5 is H, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.3 alkoxy, NR.sup.7 R.sup.8, or CONR.sup.7 R.sup.8 ; R.sup.6 is H, C.sub.1 -C.sub.6 alkyl, (C.sub.1 -C.sub.3 alkoxy) C.sub.2 -C.sub.6 alkyl, hydroxy C.sub.2 -C.sub.6 alkyl, (R.sup.7 R.sup.8 N)C.sub.2 -C.sub.6 alkyl, (R.sup.7 R.sup.8 NCO)C.sub.1 -C.sub.6 alkyl, CONR.sup.7 R.sup.8, CSNR.sup.7 R.sup.8 or C(NH)NR.sup.7 R.sup.8 ; R.sup.7 and R.sup.8 are each independently H, C.sub.1 -C.sub.4 alkyl, (C.sub.1 -C.sub.3 alkoxy)C.sub.2 -C.sub.4 alkyl or hydroxy C.sub.2 -C.sub.4 alkyl; and pharmaceutically acceptable salts thereof, are selective cGMP PDE inhibitors useful in the treatment of cardiovascular disorders such as angina, hypertension, heart failure and atherosclerosis.

Pyrazolopyrimidinone antianginal agents

Growing community of inventors

Sandwich, United Kingdom

David Graham Brown